Citation: | Wen Wu, Xiangyan Huang. Ceftazidime-induced immune hemolytic anemia: a case report[J]. Blood&Genomics, 2023, 7(1): 71-73. doi: 10.46701/BG.2023012023002 |
[1] |
Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes[J]. Immunohematology, 2014, 30(2): 44–54.
|
[2] |
Garratty G. Immune hemolytic anemia associated with drug therapy[J]. Blood Rev, 2010, 24(4–5): 143−150. doi: 10.1016/j.blre.2010.06.004
|
[3] |
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239−245. doi: 10.1038/clpt.1981.154
|
[4] |
Choi SH, Koh Y. Ceftazidime for respiratory infections[J]. Expert Opin Pharmacother, 2012, 13(14): 2097−109. doi: 10.1517/14656566.2012.721777
|
[5] |
Chen F, Zhan Z. Severe drug-induced immune haemolytic anaemia due to ceftazidime[J]. Blood Transfus, 2014, 12(3): 435−437. doi: 10.2450/2014.0237-13
|
[6] |
Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia[J]. Br J Haematol, 2017, 177(2): 208−220. doi: 10.1111/bjh.14654
|